Interviews

Gregory J. Riely, MD, PhD, vice chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses treatment considerations for older patients with lung cancer.

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia (ALL).

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, discusses the utility of oncoplastic surgery.

Hassan Arshad, MD, assistant professor of oncology, head and neck surgeon, Department of Head and Neck Surgery/Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, discusses the future of treating head and neck cancer and the challenges behind treating the disease.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, on the use of angiogenesis inhibitors for the treatment of metastatic gastric cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.

Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses two ongoing trials that look promising for the treatment of patients with DCIS.

C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma.

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer.

Thomas J. Lynch, MD, Yale Cancer Center, discusses actionable mutations in non-small cell lung cancer (NSCLC).

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ibrutinib, which was recently approved for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.

Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, discusses photodynamic therapy for the treatment of mesothelioma.

Robert Dreicer, MD, MS, Cleveland Clinic Lerner College of Medicine, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

Boris Kuvshinoff II, MD, MBA, associate professor, Division of Gastrointestinal/Endocrine Surgery, Department of Surgical Oncology, director, Liver and Pancreas Tumor Center, Roswell Park Cancer Institute, discusses microwave ablation therapy for the treatment of liver cancer.

Sunil Verma, MD, MSEd, FRCPC, University of Toronto, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses advances in the treatment of patients with metastatic HER2-positive breast cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses the challenges associated with measuring tumor heterogeneity.

Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses breast conservation in patients with multiple ipsilateral tumors.

Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, comments on the impact of targeted therapies for the treatment of chronic lymphocytic leukemia (CLL).

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.